,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,485,1,8,,26719809,3357,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
1,631,1,4,,26719809,3357,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
2,631,1,4,,26719809,3357,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
3,731,1,5,,26719809,3357,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
4,731,1,5,,26719809,3357,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
5,781,1,1,,26719809,3357,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
6,782,1,2,,26719809,3357,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
7,782,1,2,,26719809,3357,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
8,880,2,1,,26719809,3357,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
9,880,2,1,,26719809,3357,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
10,950,1,1,,26719809,3357,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
11,951,1,1,,26719809,3357,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
12,952,1,1,,26719809,3357,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
13,1001,2,2,,26719809,3357,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
14,1006,1,6,,26719809,3357,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
15,1007,1,1,,26719809,3357,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
16,1008,1,2,,26719809,3357,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
17,1009,1,2,,26719809,3357,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
18,1012,1,4,,26719809,3357,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
19,1016,1,4,,26719809,3357,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
20,1018,2,5,,26719809,3357,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
21,1019,1,4,,26719809,3357,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
22,1020,1,5,,26719809,3357,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
23,1021,1,1,,26719809,3357,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
24,1022,1,1,,26719809,3357,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
25,1027,1,3,,26719809,3357,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
26,1032,1,2,,26719809,3357,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
27,1032,1,2,,26719809,3357,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
28,1040,1,2,,26719809,3357,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
29,1048,1,1,,26719809,3357,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
30,1048,1,1,,26719809,3357,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
31,1049,1,1,,26719809,3357,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
32,1049,1,1,,26719809,3357,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
33,1051,1,1,,26719809,3357,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
34,1051,1,1,,26719809,3357,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
35,1066,1,2,,26719809,3357,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
36,1085,1,1,,26719809,3357,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
37,1135,1,3,,26719809,3357,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
38,1136,1,3,,26719809,3357,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
39,1203,1,3,,26719809,3357,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
40,1209,2,2,,26719809,3357,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
41,1214,1,4,,26719809,3357,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
42,1216,1,5,,26719809,3357,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
43,1217,1,4,,26719809,3357,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
44,1220,2,2,,26719809,3357,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
45,1222,1,6,,26719809,3357,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
46,1229,1,3,,26719809,3357,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
47,1236,1,1,,26719809,3357,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
48,1251,1,1,,26719809,3357,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
49,1274,1,2,,26719809,3357,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
50,1304,1,2,,26719809,3357,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
51,1321,1,2,,26719809,3357,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
52,1325,1,2,,26719809,3357,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
53,1359,1,4,,26719809,3357,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
54,1362,1,2,,26719809,3357,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
55,1415,1,2,,26719809,3357,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
56,1415,1,2,,26719809,3357,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
57,1416,1,2,,26719809,3357,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
58,1423,1,2,,26719809,3357,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
59,1423,1,2,,26719809,3357,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
60,1424,1,1,,26719809,3357,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
61,1434,2,3,,26719809,3357,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
62,1434,2,3,,26719809,3357,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
63,1439,1,1,,26719809,3357,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
64,1439,1,1,,26719809,3357,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
65,1440,1,1,,26719809,3357,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
66,1440,1,1,,26719809,3357,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
67,1441,1,1,,26719809,3357,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
68,1441,1,1,,26719809,3357,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
69,1443,1,3,,26719809,3357,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
70,1445,1,1,,26719809,3357,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
71,1446,1,3,,26719809,3357,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
72,1448,1,3,,26719809,3357,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
73,1454,1,1,,26719809,3357,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
74,1456,1,1,,26719809,3357,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
75,1460,1,3,,26719809,3357,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
76,1461,1,2,,26719809,3357,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
77,1463,1,1,,26719809,3357,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
78,1466,1,2,,26719809,3357,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
79,1467,1,3,,26719809,3357,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
80,1468,1,1,,26719809,3357,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
81,1469,1,1,,26719809,3357,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
82,1471,2,1,,50112812,3357,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
83,1477,1,1,,26719809,3357,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
84,1479,1,2,,26719809,3357,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
85,1481,1,2,,26719809,3357,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
86,1486,1,3,,26719809,3357,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
87,1490,2,1,,26719809,3357,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
88,1490,2,1,,50112812,3357,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
89,1496,1,4,,26719809,3357,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
90,1496,1,4,,26719809,3357,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
91,1509,1,2,,26719809,3357,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
92,1510,1,3,,26719809,3357,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
93,1515,1,2,,26719809,3357,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
94,1527,1,3,,26719809,3357,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
95,1529,1,1,,26719809,3357,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
96,1530,1,1,,26719809,3357,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
97,1531,1,1,,26719809,3357,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
98,1533,1,1,,26719809,3357,Inactive,15610402.0,888704.0,,,Rml C and D inhibition 384-well mixture HTS from 1536-well compound plates,Screening,,
99,1533,1,1,,26719809,3357,Inactive,15610601.0,887352.0,,,Rml C and D inhibition 384-well mixture HTS from 1536-well compound plates,Screening,,
100,1556,1,4,,26719809,3357,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
101,1565,2,2,,26719809,3357,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
102,1566,2,3,,26719809,3357,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
103,1578,3,2,,26719809,3357,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
104,1619,1,2,,26719809,3357,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
105,1625,2,2,,26719809,3357,Inactive,,,,EC50,HCS for Compounds that Up-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
106,1626,1,2,,26719809,3357,Inconclusive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
107,1628,2,2,,26719809,3357,Inactive,,,,IC50,HCS for Compounds that Down-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
108,1631,3,1,,26719809,3357,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
109,1634,3,1,,26719809,3357,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
110,1654,2,2,,26719809,3357,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
111,1656,2,2,,26719809,3357,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
112,1665,2,2,,26719809,3357,Inactive,4503131.0,1499.0,,IC50_Mean,High Throughput Imaging Assay for Beta-Catenin,Confirmatory,,
113,1688,1,1,,50112812,3357,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
114,1700,1,2,,26719809,3357,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
115,1706,1,2,,26719809,3357,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
116,1721,1,2,,26719809,3357,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
117,1722,1,2,,26719809,3357,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
118,1766,1,1,,26719809,3357,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
119,1766,1,1,,26719809,3357,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
120,1766,1,1,,50112812,3357,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
121,1766,1,1,,50112812,3357,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
122,1768,1,1,,26719809,3357,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
123,1768,1,1,,26719809,3357,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
124,1768,1,1,,50112812,3357,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
125,1768,1,1,,50112812,3357,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
126,1775,1,2,,26719809,3357,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
127,1776,1,2,,26719809,3357,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
128,1777,3,2,,26719809,3357,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
129,1778,3,3,,26719809,3357,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
130,1779,2,2,,26719809,3357,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
131,1789,1,2,,26719809,3357,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
132,1800,1,2,,26719809,3357,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
133,1817,2,2,,26719809,3357,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
134,1822,1,3,,26719809,3357,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
135,1825,1,1,,26719809,3357,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
136,1845,1,2,,26719809,3357,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
137,1861,2,1,,26719809,3357,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
138,1863,2,1,,26719809,3357,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
139,1865,1,1,,26719809,3357,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
140,1868,1,4,,26719809,3357,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
141,1903,2,3,,26719809,3357,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
142,1961,2,2,,26719809,3357,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
143,1984,1,3,,26719809,3357,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
144,1986,1,2,,26719809,3357,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
145,2006,3,2,,26719809,3357,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
146,2006,3,2,,26719809,3357,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
147,2006,3,2,,26719809,3357,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
148,2012,3,2,,26719809,3357,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
149,2013,2,2,,26719809,3357,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
150,2014,3,2,,26719809,3357,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
151,2058,3,2,,26719809,3357,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
152,2071,2,2,,26719809,3357,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
153,2073,2,3,,26719809,3357,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
154,2073,2,3,,26719809,3357,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
155,2100,1,1,,26719809,3357,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
156,2101,1,1,,26719809,3357,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
157,2107,1,1,,26719809,3357,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
158,2112,1,1,,26719809,3357,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
159,2147,1,1,,26719809,3357,Active,221046486.0,,3.1623,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
160,2242,1,1,,26719809,3357,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
161,2288,1,1,,26719809,3357,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
162,2289,1,1,,26719809,3357,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
163,2314,1,2,,26719809,3357,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
164,2314,1,2,,26719809,3357,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
165,2315,1,2,,26719809,3357,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
166,2315,1,2,,26719809,3357,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
167,2451,1,2,,26719809,3357,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
168,2472,1,2,,26719809,3357,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
169,2517,2,1,,26719809,3357,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
170,2528,1,2,,26719809,3357,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
171,2528,1,2,,50112812,3357,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
172,2546,1,1,,26719809,3357,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
173,2546,1,1,,50112812,3357,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
174,2549,1,1,,26719809,3357,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
175,2551,1,1,,26719809,3357,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
176,2551,1,1,,50112812,3357,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
177,2662,2,1,,26719809,3357,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
178,2662,2,1,,50112812,3357,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
179,2675,1,1,,26719809,3357,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
180,2676,1,2,,26719809,3357,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
181,2685,1,1,,26719809,3357,Inconclusive,,,3.6626,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
182,2732,1,1,,26719809,3357,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
183,11143,6,2,,103163873,3357,Unspecified,,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,Other,1992128.0,
184,11144,6,2,,103163873,3357,Unspecified,,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,Other,1992128.0,
185,13688,6,2,,103163873,3357,Unspecified,,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,Other,1992128.0,
186,13689,6,2,,103163873,3357,Unspecified,,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,Other,1992128.0,
187,24517,5,2,,103163873,3357,Unspecified,,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its half life after 40 mg/kg of intramuscular administration in mice.,Other,1992128.0,
188,24518,5,2,,103163873,3357,Unspecified,,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its half life after 40 mg/kg of peroral administration in mice.,Other,1992128.0,
189,38472,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Bacteroides thetaiotaomicron 62B,Other,1588561.0,
190,38484,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Bacteroides fragilis F117A,Other,1588561.0,
191,40339,6,2,,103163873,3357,Unspecified,,,,,Compound was tested in vitro for its antibacterial activity (minimum inhibitory concentration) against Bacteroides fragilis A 22862.,Other,1992128.0,
192,40940,6,2,,103163873,3357,Unspecified,,,,,In vitro for antibacterial activity against Bacillus subtilis ATCC 585369,Other,1315393.0,
193,41400,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against bacteroides fragilis S2,Other,1588561.0,
194,42680,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Clostridium difficile 651,Other,1588561.0,
195,42681,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Clostridium difficile 701,Other,1588561.0,
196,42688,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Clostridium perfringens 13424,Other,1588561.0,
197,50552,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against citrobacter freundii BS-16 (constitutive beta-lactamase producer),Other,1588561.0,
198,50857,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against clostridium histolyticum 503-86,Other,1588561.0,
199,51918,7,2,,103163873,3357,Unspecified,,,,,Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity),Other,1469702.0,
200,52927,6,2,,103163873,3357,Unspecified,,,,,In vivo activity in murine against Citrobacter freundii BS#16 infection after sc administration.,Other,1847430.0,
201,52941,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Citrobacter freundii BS 16,Other,1847430.0,
202,52946,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity was determined against Citrobacter freundii BS-16,Other,2153215.0,
203,64080,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Escherichia coli 257,Other,1588561.0,
204,64898,6,2,,103163873,3357,Unspecified,,,,,In vitro for antibacterial activity against Escherichia coli 1346 (Ec(A)),Other,1315393.0,
205,64899,6,2,,103163873,3357,Unspecified,,,,,In vitro for antibacterial activity against Escherichia coli 1527E (Ec(C)),Other,1315393.0,
206,64900,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Escherichia coli 25922,Other,1588561.0,
207,65038,6,2,,103163873,3357,Unspecified,,,,,In vitro for antibacterial activity against Escherichia coli B (Ec(B)),Other,1315393.0,
208,65043,6,2,,103163873,3357,Unspecified,,,,,Effect on replication DNA biosynthesis in Escherichia coli H560 (permeabilised cells).,Other,1588561.0,
209,65224,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Escherichia coli TEM-1 (constitutive beta-lactamase producer),Other,1588561.0,
210,65225,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Escherichia coli UB1005 (nalidixic acid-resistant strain),Other,1588561.0,
211,66227,6,2,,103163873,3357,Unspecified,,,,,In vitro for antibacterial activity against Enterobacter cloacae P99,Other,1315393.0,
212,66230,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against enterobacter cloacae P99 (constitutive beta-lactamase producer),Other,1588561.0,
213,66246,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity was determined against Enterobacter cloacae P99 (Class Ia beta-lactamase overproducer),Other,2153215.0,
214,67228,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Enterococcus faecalis A 9809,Other,1992128.0,
215,67402,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity was determined against Enterococcus faecalis ATCC 29212,Other,2153215.0,
216,67999,6,2,,103163873,3357,Unspecified,,,,,In vivo activity in murine against Enterobacter cloacae 5699 infection after sc administration.,Other,1847430.0,
217,68180,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Enterobacter cloacae A 9656,Other,1992128.0,
218,68184,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Enterobacter cloacae 5699,Other,1847430.0,
219,68185,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Enterobacter cloacae P99,Other,1847430.0,
220,68506,6,2,,103163873,3357,Unspecified,,,,,Minimum inhibitory concentration against Enterobacter cloacae. (MA2446).,Other,2834557.0,
221,68666,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity was determined against Escherichia coli ATCC 25922,Other,2153215.0,
222,68667,8,1,,103163873,3357,Active,,,,,In vitro antibacterial activity was determined against Escherichia coli DC-O,Other,2153215.0,
223,68668,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity was determined against Escherichia coli TEM-1 (TEM-1 (class IIIa) beta-lactamase producer),Other,2153215.0,
224,68822,7,2,,103163873,3357,Unspecified,,,,,In vivo activity in murine against Escherichia coli 257 infection after sc administration.,Other,1847430.0,
225,68823,6,2,,103163873,3357,Unspecified,,,,,In vivo effective dose against mice infected with Escherichia coli 257,Other,2153215.0,
226,69469,6,2,,103163873,3357,Unspecified,,,,,Minimum inhibitory concentration against Escherichia coli (H560),Other,2834557.0,
227,69470,6,2,,103163873,3357,Unspecified,,,,,Minimum inhibitory concentration against Escherichia coli (vogel),Other,2834557.0,
228,69782,6,3,,103163873,3357,Unspecified,,,,,Antibacterial activity against Escherichia coli (H560),Other,3005575.0,
229,69784,6,3,,103163873,3357,Unspecified,,,,,Antibacterial activity against Escherichia coli (vogel),Other,3005575.0,
230,70591,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Escherichia coli A 15119,Other,1992128.0,
231,70760,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Escherichia coli 257,Other,1847430.0,
232,74727,7,2,,103163873,3357,Unspecified,,,,,Antibacterial activity against five Gram-negative bacteria,Other,1469702.0,
233,74853,7,3,,103163873,3357,Unspecified,,,,,Antibacterial activity against five Gram-positive bacteria targeting topoisomerase II (DNA gyrase B GyrB),Other,1469702.0,
234,78550,5,1,,103163873,3357,Unspecified,,,,,Concentration required for 50% inhibition of gyrase.,Other,2834557.0,
235,78687,5,1,,103163873,3357,Unspecified,,,,,Lowest concentration necessary to induce DNA gyrase-mediated cleavage of DNA,Other,2834557.0,
236,78688,6,5,,103163873,3357,Unspecified,,,,,Inhibitory concentration in supercoiling inhibition Escherichia coli DNA gyrase assay,Other,3005575.0,
237,78707,6,4,,103163873,3357,Unspecified,,,,,MIC at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 ug/mL by using Gyrase Induced DNA-Cleavage assay,Other,3005575.0,
238,78708,5,1,,103163873,3357,Unspecified,,,,,Inhibitory activity against Escherichia coli DNA gyrase (represented as MNEC),Other,1315393.0,
239,85970,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Haemophilus influenzae A 21515,Other,1992128.0,
240,93887,6,2,,103163873,3357,Unspecified,,,,,Minimum inhibitory concentration against Klebsiella pneumoniae (MGH-2),Other,2834557.0,
241,94224,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against klebsiella pneumoniae A,Other,1588561.0,
242,95533,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Klebsiella pneumoniae A 9664,Other,1992128.0,
243,95878,6,2,,103163873,3357,Unspecified,,,,,In vitro for antibacterial activity against Klebsiella oxytoca 1082E,Other,1315393.0,
244,95885,6,3,,103163873,3357,Unspecified,,,,,Antibacterial activity against Klebsiella pneumonia (MGH-2),Other,3005575.0,
245,95902,6,2,,103163873,3357,Unspecified,,,,,In vivo activity in murine against Klebsiella pneumoniae A infection after sc administration.,Other,1847430.0,
246,96244,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Klebsiella pneumoniae A,Other,1847430.0,
247,123058,8,1,,103163873,3357,Active,,,,,In vitro antibacterial activity was determined against Micrococcus luteus PCI,Other,2153215.0,
248,123084,6,2,,103163873,3357,Unspecified,,,,,In vitro for antibacterial activity against Micrococcus luteus ATCC 8340,Other,1315393.0,
249,125256,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Morganella morganii A 15153,Other,1992128.0,
250,135327,6,1,,103163873,3357,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
251,140679,3,4,,103163873,3357,Unspecified,,,,,Compound was evaluated in vivo in urine sample collected over 24 hours for its concentration after 40 mg/kg intramuscular administration to mice,Other,1992128.0,
252,140680,3,4,,103163873,3357,Unspecified,,,,,Compound was evaluated in vivo in urine sample collected over 24 hours for its concentration after 40 mg/kg peroral administration to mice,Other,1992128.0,
253,150911,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Ps. aeruginosa 18SH (constitutive beta-lactamase producer),Other,1588561.0,
254,152305,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Proteus mirabilis 90,Other,1588561.0,
255,162744,6,2,,103163873,3357,Unspecified,,,,,"In vitro antibacterial activity (minimum inhibitory concentration, MIC) against Proteus mirabilis A 9900",Other,1992128.0,
256,162756,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity was determined against Proteus mirabilis 90,Other,2153215.0,
257,163052,6,2,,103163873,3357,Unspecified,,,,,Minimum inhibitory concentration against Providencia rettgeri. (M1771),Other,2834557.0,
258,163100,6,2,,103163873,3357,Unspecified,,,,,Minimum inhibitory concentration against Pseudomonas aeruginosa. (UI-18),Other,2834557.0,
259,163252,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity was determined against Proteus vulgaris 1028 BC (Class Ic beta-lactamase overproducer),Other,2153215.0,
260,163568,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against proteus vulgaris ATCC 6380 (constitutive beta-lactamase producer),Other,1588561.0,
261,163780,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity was determined against Pseudomonas aeruginosa ATCC 27853,Other,2153215.0,
262,163937,6,2,,103163873,3357,Unspecified,,,,,In vitro for antibacterial activity against Pseudomonas aeruginosa 799/61,Other,1315393.0,
263,163943,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Pseudomonas aeruginosa 8780,Other,1588561.0,
264,164081,7,2,,103163873,3357,Unspecified,,,,,In vivo activity in murine against Pseudomonas aeruginosa 5712 infection after sc administration.,Other,1847430.0,
265,164385,6,3,,103163873,3357,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa (UI-18),Other,3005575.0,
266,164733,6,2,,103163873,3357,Unspecified,,,,,"Compound was tested in vitro for its antibacterial activity (minimum inhibitory concentration, MIC) against Pseudomonas aeruginosa A 9843",Other,1992128.0,
267,164887,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Pseudomonas aeruginosa 5712,Other,1847430.0,
268,165204,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity was determined against Pseudomonas aeruginosa 18S/H (Class Id beta-lactamase overproducer),Other,2153215.0,
269,201252,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Staphylococcus aureus 67(methicillin resistant),Other,1588561.0,
270,201254,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Staphylococcus aureus 753 (constitutive beta-lactamase producer),Other,1588561.0,
271,201413,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against staphylococcus aureus smith,Other,1588561.0,
272,202125,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Streptococcus pyogenes 4,Other,1588561.0,
273,203135,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Serratia marcescens SM,Other,1847430.0,
274,203141,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity was determined against Serratia marcescens 1071,Other,2153215.0,
275,203321,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against serratia marcescens SM (constitutive beta-lactamase producer),Other,1588561.0,
276,205371,7,2,,103163873,3357,Unspecified,,,,,In vivo activity in murine against Serratia marcescens SM infection after sc administration.,Other,1847430.0,
277,205394,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity (minimum inhibitory concentration) against Serratia marcescens A 20019.,Other,1992128.0,
278,205531,6,2,,103163873,3357,Unspecified,,,,,Minimum inhibitory concentration against Staphylococcus aureus (H-228).,Other,2834557.0,
279,205543,6,2,,103163873,3357,Unspecified,,,,,Minimum inhibitory concentration against Staphylococcus aureus (UC76).,Other,2834557.0,
280,205830,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Staphylococcus aureus A 24227,Other,1992128.0,
281,205831,6,2,,103163873,3357,Unspecified,,,,,"In vitro antibacterial activity (minimum inhibitory concentration, MIC) against Staphylococcus aureus A 9537.",Other,1992128.0,
282,206117,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Staphylococcus aureus 95(MR),Other,1847430.0,
283,206118,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Staphylococcus aureus Smith(MS),Other,1847430.0,
284,206506,6,2,,103163873,3357,Unspecified,,,,,In vitro for antibacterial activity against Staphylococcus haemolyticus 75 (quinolone-resistant),Other,1315393.0,
285,206552,6,2,,103163873,3357,Unspecified,,,,,In vivo activity in murine against Staphylococcus aureus 753(MR) infection after sc administration.,Other,1847430.0,
286,206553,6,2,,103163873,3357,Unspecified,,,,,In vivo activity in murine against Staphylococcus aureus Smith (MS) infection after sc administration.,Other,1847430.0,
287,206755,6,2,,103163873,3357,Unspecified,,,,,"In vitro antibacterial activity was determined against Staphylococcus aureus 1059B ( inducible, high level beta-lactamase producer)",Other,2153215.0,
288,206757,6,2,,103163873,3357,Unspecified,,,,,"In vitro antibacterial activity was determined against Staphylococcus aureus 95 (Methicillin-resistant, high-level beta-lactamase producer)",Other,2153215.0,
289,206759,6,2,,103163873,3357,Unspecified,,,,,"In vitro antibacterial activity was determined against Staphylococcus aureus ATCC 29213 (inducible, low level beta-lactamase producer)",Other,2153215.0,
290,207175,6,3,,103163873,3357,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus (H228),Other,3005575.0,
291,207405,6,2,,103163873,3357,Unspecified,,,,,In vitro for antibacterial activity against Staphylococcus aureus 887,Other,1315393.0,
292,208022,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity was determined against Streptococcus pneumoniae 6301,Other,2153215.0,
293,208120,8,1,,103163873,3357,Active,,,,,In vitro antibacterial activity was determined against Streptococcus pneumoniae 6301,Other,2153215.0,
294,208310,6,2,,103163873,3357,Unspecified,,,,,Minimum inhibitory concentration against Streptococcus pneumoniae (SV-1).,Other,2834557.0,
295,208788,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against streptococcus pneumoniae 6301,Other,1588561.0,
296,209100,7,2,,103163873,3357,Unspecified,,,,,In vivo activity in murine against Streptococcus pyogenes 4 infection after sc administration.,Other,1847430.0,
297,209116,6,2,,103163873,3357,Unspecified,,,,,In vivo effective dose against mice infected with streptococcus pyogenes 4,Other,2153215.0,
298,209248,6,2,,103163873,3357,Unspecified,,,,,Minimum inhibitory concentration against Streptococcus faecalis (MGH-2).,Other,2834557.0,
299,209454,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Streptococcus pyogenes 4,Other,1847430.0,
300,209611,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity was determined against Streptococcus pyogenes 4,Other,2153215.0,
301,209763,6,2,,103163873,3357,Unspecified,,,,,Minimum inhibitory concentration against Streptococcus pyogenes (C203).,Other,2834557.0,
302,209864,7,2,,103163873,3357,Unspecified,,,,,In vivo activity in murine against Streptococcus pneumoniae 6301 infection after sc administration.,Other,1847430.0,
303,210022,6,3,,103163873,3357,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae (SV-1),Other,3005575.0,
304,210201,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Streptococcus pneumoniae A 9585,Other,1992128.0,
305,210205,6,2,,103163873,3357,Unspecified,,,,,In vitro antibacterial activity against Streptococcus pneumoniae 6301,Other,1847430.0,
306,222085,6,2,,103163873,3357,Unspecified,,,,,Minimum inhibitory concentration against gram-negative enterobacteriaceae.,Other,2834557.0,
307,241266,6,4,,103163873,3357,Unspecified,,,,,Inhibitory concentration against DNA gyrase of Staphylococcus aureus,Other,15857125.0,
308,244844,6,2,,103163873,3357,Unspecified,,,,,In vitro minimum inhibitory concentration against Escherichia coli NIHJ JC-2,Other,15857125.0,
309,244848,6,2,,103163873,3357,Unspecified,,,,,In vitro minimum inhibitory concentration against Staphylococcus aureus Smith,Other,15857125.0,
310,244860,6,2,,103163873,3357,Unspecified,,,,,In vitro minimum inhibitory concentration against Pseudomonas aeruginosa IID1210,Other,15857125.0,
311,244879,6,2,,103163873,3357,Unspecified,,,,,In vitro minimum inhibitory concentration against Streptococcus pneumoniae type III,Other,15857125.0,
312,425652,7,2,,103163873,3357,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
313,425653,7,2,,103163873,3357,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
314,444050,7,1,,103163873,3357,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
315,444051,6,2,,103163873,3357,Unspecified,,,,,Total clearance in human,Other,20070106.0,
316,444052,6,2,,103163873,3357,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
317,444053,6,2,,103163873,3357,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
318,444054,6,1,,103163873,3357,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
319,444055,3,3,,103163873,3357,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
320,444056,3,3,,103163873,3357,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
321,444057,3,3,,103163873,3357,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
322,444058,6,2,,103163873,3357,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
323,455986,3,5,,103163873,3357,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
324,463254,1,1,,26719809,3357,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
325,485281,1,1,,26719809,3357,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
326,485290,1,1,,26719809,3357,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
327,485294,1,1,,26719809,3357,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
328,485297,1,1,,26719809,3357,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
329,485298,1,1,,26719809,3357,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
330,485313,1,2,,26719809,3357,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
331,485314,1,1,,26719809,3357,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
332,485341,1,1,,26719809,3357,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
333,485344,1,1,,26719809,3357,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
334,485347,1,2,,26719809,3357,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
335,485353,2,1,,26719809,3357,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
336,485358,1,1,,26719809,3357,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
337,485364,1,1,,26719809,3357,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
338,485367,1,2,,26719809,3357,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
339,488837,1,1,,26719809,3357,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
340,492947,1,1,,26719809,3357,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
341,492961,1,1,,50112812,3357,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
342,493014,1,1,,26719809,3357,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
343,493056,1,1,,26719809,3357,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
344,493084,1,1,,26719809,3357,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
345,504327,1,1,,26719809,3357,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
346,504327,1,1,,50112812,3357,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
347,504332,1,1,,26719809,3357,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
348,504332,1,1,,50112812,3357,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
349,504333,1,1,,26719809,3357,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
350,504651,1,1,,26719809,3357,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
351,504652,1,1,,26719809,3357,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
352,504660,1,1,,26719809,3357,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
353,504749,1,3,,50112812,3357,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
354,504749,1,3,1.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
355,504749,1,3,2.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
356,504749,1,3,3.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
357,504749,1,3,4.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
358,504749,1,3,5.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
359,504749,1,3,6.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
360,504749,1,3,7.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
361,504749,1,3,8.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
362,504749,1,3,9.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
363,504749,1,3,10.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
364,504749,1,3,11.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
365,504749,1,3,12.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
366,504749,1,3,13.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
367,504749,1,3,14.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
368,504749,1,3,15.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
369,504749,1,3,16.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
370,504749,1,3,17.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
371,504749,1,3,18.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
372,504749,1,3,19.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
373,504749,1,3,20.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
374,504749,1,3,21.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
375,504749,1,3,22.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
376,504749,1,3,23.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
377,504749,1,3,24.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
378,504749,1,3,25.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
379,504749,1,3,26.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
380,504749,1,3,27.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
381,504749,1,3,28.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
382,504749,1,3,29.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
383,504749,1,3,30.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
384,504749,1,3,31.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
385,504749,1,3,32.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
386,504749,1,3,33.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
387,504749,1,3,34.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
388,504749,1,3,35.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
389,504749,1,3,36.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
390,504749,1,3,37.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
391,504749,1,3,38.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
392,504749,1,3,39.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
393,504749,1,3,40.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
394,504749,1,3,41.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
395,504749,1,3,42.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
396,504749,1,3,43.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
397,504749,1,3,44.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
398,504749,1,3,45.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
399,504749,1,3,46.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
400,504749,1,3,47.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
401,504749,1,3,48.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
402,504749,1,3,49.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
403,504749,1,3,50.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
404,504749,1,3,51.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
405,504749,1,3,52.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
406,504749,1,3,53.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
407,504749,1,3,54.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
408,504749,1,3,55.0,50112812,3357,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
409,504749,1,3,56.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
410,504749,1,3,57.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
411,504749,1,3,58.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
412,504749,1,3,59.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
413,504749,1,3,60.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
414,504749,1,3,61.0,50112812,3357,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
415,504810,1,2,,26719809,3357,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
416,504812,1,2,,26719809,3357,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
417,504832,1,1,,50112812,3357,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
418,504834,1,1,,50112812,3357,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
419,504842,1,1,,26719809,3357,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
420,504847,1,1,,50112812,3357,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
421,504865,1,1,,50112812,3357,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
422,540209,4,3,,103163873,3357,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
423,540210,4,3,,103163873,3357,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
424,540211,2,5,,103163873,3357,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
425,540212,4,3,,103163873,3357,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
426,540213,4,3,,103163873,3357,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
427,540214,4,3,,103163873,3357,Unspecified,,,,,Clearance in rat after iv administration,Other,15920768.0,
428,540215,3,2,,103163873,3357,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,15920768.0,
429,540216,4,3,,103163873,3357,Unspecified,,,,,Clearance in dog after iv administration,Other,15920768.0,
430,540217,4,3,,103163873,3357,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,15920768.0,
431,540218,4,3,,103163873,3357,Unspecified,,,,,Clearance in monkey after iv administration,Other,15920768.0,
432,540219,4,3,,103163873,3357,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,15920768.0,
433,540220,4,3,,103163873,3357,Unspecified,,,,,Clearance in human after iv administration,Other,15920768.0,
434,540221,4,3,,103163873,3357,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,15920768.0,
435,540230,2,5,,103163873,3357,Unspecified,,,,,Dose normalised AUC in rat after po administration,Other,16019946.0,
436,540231,2,5,,103163873,3357,Unspecified,,,,,Dose normalised AUC in dog after po administration,Other,16019946.0,
437,540232,2,5,,103163873,3357,Unspecified,,,,,Dose normalised AUC in monkey after po administration,Other,16019946.0,
438,540233,2,5,,103163873,3357,Unspecified,,,,,Dose normalised AUC in human after po administration,Other,16019946.0,
439,540275,1,1,,26719809,3357,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
440,540277,1,1,,26719809,3357,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
441,588342,1,1,,26719809,3357,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
442,588579,1,1,,50112812,3357,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
443,588834,2,1,,50112812,3357,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
444,592681,1,4,,103163873,3357,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
445,602332,1,1,,50112812,3357,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
446,624030,1,2,,50112812,3357,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
447,624031,1,2,,50112812,3357,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
448,624032,1,2,,50112812,3357,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
449,624044,1,2,,50112812,3357,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
450,624170,1,1,,50112812,3357,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
451,624172,1,1,,50112812,3357,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
452,624173,1,3,,50112812,3357,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
453,624296,1,1,,50112812,3357,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
454,624297,1,1,,50112812,3357,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
455,624349,1,2,,92309164,3357,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
456,625144,5,5,,103163873,3357,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
457,625145,4,7,,103163873,3357,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
458,625146,5,5,,103163873,3357,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
459,625147,4,7,,103163873,3357,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
460,625148,4,7,,103163873,3357,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
461,625149,4,7,,103163873,3357,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
462,625150,5,5,,103163873,3357,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
463,625151,4,7,,103163873,3357,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
464,625152,4,7,,103163873,3357,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
465,625153,4,7,,103163873,3357,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
466,625154,4,7,,103163873,3357,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
467,625155,4,7,,103163873,3357,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
468,625156,1,9,,103163873,3357,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
469,625157,6,2,,103163873,3357,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
470,625158,3,4,,103163873,3357,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
471,625159,5,5,,103163873,3357,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
472,625160,1,9,,103163873,3357,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
473,625161,4,7,,103163873,3357,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
474,625162,4,7,,103163873,3357,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
475,625163,4,7,,103163873,3357,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
476,625164,1,6,,103163873,3357,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
477,625165,3,4,,103163873,3357,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
478,625166,3,4,,103163873,3357,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
479,625167,5,5,,103163873,3357,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
480,625168,4,7,,103163873,3357,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
481,625169,1,6,,103163873,3357,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
482,625170,3,4,,103163873,3357,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
483,625171,4,7,,103163873,3357,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
484,625172,4,7,,103163873,3357,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
485,625173,5,5,,103163873,3357,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
486,625174,5,5,,103163873,3357,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
487,625175,5,5,,103163873,3357,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
488,625176,1,9,,103163873,3357,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
489,625177,5,5,,103163873,3357,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
490,625178,5,5,,103163873,3357,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
491,625179,1,9,,103163873,3357,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
492,625180,5,5,,103163873,3357,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
493,625181,5,5,,103163873,3357,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
494,625182,5,5,,103163873,3357,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
495,625183,5,5,,103163873,3357,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
496,625184,5,5,,103163873,3357,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
497,625185,5,5,,103163873,3357,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
498,625186,5,5,,103163873,3357,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
499,625187,5,5,,103163873,3357,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
500,625188,1,9,,103163873,3357,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
501,625189,1,7,,103163873,3357,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
502,625190,4,5,,103163873,3357,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
503,625191,4,7,,103163873,3357,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
504,625192,4,7,,103163873,3357,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
505,625193,5,5,,103163873,3357,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
506,625194,4,7,,103163873,3357,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
507,625195,4,7,,103163873,3357,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
508,625196,5,6,,103163873,3357,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
509,625197,3,4,,103163873,3357,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
510,625198,4,7,,103163873,3357,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
511,625199,4,7,,103163873,3357,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
512,625200,4,7,,103163873,3357,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
513,625201,4,7,,103163873,3357,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
514,625202,4,7,,103163873,3357,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
515,625203,4,7,,103163873,3357,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
516,625204,4,7,,103163873,3357,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
517,625205,4,7,,103163873,3357,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
518,625206,4,7,,103163873,3357,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
519,625207,4,7,,103163873,3357,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
520,625208,5,5,,103163873,3357,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
521,625209,4,7,,103163873,3357,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
522,625210,3,4,,103163873,3357,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
523,625211,1,6,,103163873,3357,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
524,625212,3,4,,103163873,3357,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
525,625213,4,7,,103163873,3357,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
526,625214,1,9,,103163873,3357,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
527,625215,3,4,,103163873,3357,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
528,625216,3,4,,103163873,3357,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
529,625217,4,7,,103163873,3357,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
530,625218,4,7,,103163873,3357,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
531,625219,3,4,,103163873,3357,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
532,625220,4,7,,103163873,3357,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
533,625221,4,7,,103163873,3357,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
534,625222,4,7,,103163873,3357,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
535,625223,4,7,,103163873,3357,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
536,625224,3,4,,103163873,3357,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
537,625225,3,4,,103163873,3357,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
538,625226,4,7,,103163873,3357,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
539,625227,4,7,,103163873,3357,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
540,625228,4,7,,103163873,3357,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
541,625229,5,5,,103163873,3357,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
542,625230,1,6,,103163873,3357,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
543,625231,4,7,,103163873,3357,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
544,625232,1,9,,103163873,3357,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
545,625233,4,7,,103163873,3357,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
546,625234,3,4,,103163873,3357,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
547,625235,4,7,,103163873,3357,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
548,625236,5,5,,103163873,3357,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
549,625237,4,7,,103163873,3357,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
550,625238,4,7,,103163873,3357,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
551,625239,4,7,,103163873,3357,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
552,625240,1,9,,103163873,3357,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
553,625241,4,7,,103163873,3357,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
554,625242,4,7,,103163873,3357,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
555,625243,5,5,,103163873,3357,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
556,625244,5,5,,103163873,3357,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
557,625245,5,5,,103163873,3357,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
558,625246,1,9,,103163873,3357,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
559,625247,5,5,,103163873,3357,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
560,625248,5,5,,103163873,3357,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
561,625249,5,5,,103163873,3357,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
562,625250,5,5,,103163873,3357,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
563,625251,5,5,,103163873,3357,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
564,625252,4,7,,103163873,3357,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
565,625253,4,7,,103163873,3357,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
566,625254,4,7,,103163873,3357,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
567,625255,4,7,,103163873,3357,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
568,625256,4,7,,103163873,3357,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
569,625257,4,7,,103163873,3357,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
570,625258,4,7,,103163873,3357,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
571,625259,4,7,,103163873,3357,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
572,625260,3,4,,103163873,3357,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
573,625261,3,4,,103163873,3357,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
574,625262,3,4,,103163873,3357,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
575,625263,4,7,,103163873,3357,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
576,625264,3,4,,103163873,3357,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
577,625265,1,6,,103163873,3357,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
578,625266,3,4,,103163873,3357,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
579,625267,3,4,,103163873,3357,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
580,625268,4,2,,103163873,3357,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
581,625268,4,2,,103163873,3357,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
582,625268,4,2,,103163873,3357,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
583,625268,4,2,,103163873,3357,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
584,625269,4,7,,103163873,3357,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
585,625270,4,7,,103163873,3357,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
586,625271,5,5,,103163873,3357,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
587,625272,3,4,,103163873,3357,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
588,625273,4,6,,103163873,3357,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
589,625274,1,6,,103163873,3357,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
590,625275,3,4,,103163873,3357,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
591,651631,4,1,,144206106,3357,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
592,651632,4,1,,144206106,3357,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
593,651633,4,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
594,651634,4,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
595,651828,1,2,,92309164,3357,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
596,652048,1,2,,144206106,3357,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
597,652051,1,1,,144206106,3357,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
598,686978,1,1,,144206106,3357,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
599,686979,1,1,,144206106,3357,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
600,720516,2,1,,144206106,3357,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
601,720532,1,1,,144206106,3357,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
602,720533,1,1,,144206106,3357,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
603,720552,2,1,,144206106,3357,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
604,720634,2,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
605,720635,2,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
606,720637,2,1,,144206106,3357,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
607,720641,1,2,,92309164,3357,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
608,720674,2,2,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
609,720675,2,2,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
610,720678,2,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
611,720679,2,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
612,720680,2,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
613,720681,2,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
614,720682,2,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
615,720683,2,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
616,720684,2,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
617,720685,2,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
618,720686,2,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
619,720687,2,2,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
620,720691,4,1,,144206106,3357,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
621,720692,3,1,,144206106,3357,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
622,720693,3,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
623,720717,1,3,,92309164,3357,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
624,720719,2,1,,144206106,3357,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
625,720725,2,1,,144206106,3357,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
626,743012,3,1,,144206106,3357,Inconclusive,,,21.1317,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
627,743014,3,1,,144206106,3357,Inconclusive,,,21.1317,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
628,743015,3,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
629,743033,3,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
630,743035,2,1,,144206106,3357,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
631,743036,2,1,,144206106,3357,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
632,743040,3,1,,144206106,3357,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
633,743041,3,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
634,743042,3,1,,144206106,3357,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
635,743053,2,1,,144206106,3357,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
636,743054,2,1,,144206106,3357,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
637,743063,2,1,,144206106,3357,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
638,743064,3,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
639,743065,3,1,,144206106,3357,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
640,743066,3,1,,144206106,3357,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
641,743067,2,1,,144206106,3357,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
642,743069,2,1,,144206106,3357,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
643,743074,2,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
644,743075,2,1,,144206106,3357,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
645,743077,2,1,,144206106,3357,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
646,743078,2,1,,144206106,3357,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
647,743079,3,1,,144206106,3357,Inconclusive,348019627.0,2099.0,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
648,743080,3,1,,144206106,3357,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
649,743081,3,1,,144206106,3357,Inconclusive,,,0.1188,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
650,743083,3,1,,144206106,3357,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
651,743084,3,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
652,743085,3,1,,144206106,3357,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
653,743086,3,1,,144206106,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
654,743091,2,1,,144206106,3357,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
655,743094,3,1,,144206106,3357,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
656,743122,2,1,,144206106,3357,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
657,743139,2,1,,144206106,3357,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
658,743140,2,1,,144206106,3357,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
659,743191,3,1,,170466056,3357,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
660,743194,3,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
661,743199,2,1,,170466056,3357,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
662,743202,4,1,,170466056,3357,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
663,743203,3,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
664,743209,3,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
665,743210,4,1,,170466056,3357,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
666,743211,3,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
667,743212,3,1,,170466056,3357,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
668,743213,3,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
669,743215,3,1,,170466056,3357,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
670,743217,3,1,,170466056,3357,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
671,743218,3,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
672,743219,3,1,,170466056,3357,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
673,743220,3,1,,170466056,3357,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
674,743221,3,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
675,743222,3,1,,170466056,3357,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
676,743223,3,1,,170466056,3357,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
677,743224,3,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
678,743225,3,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
679,743226,2,1,,170466056,3357,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
680,743227,2,1,,170466056,3357,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
681,743228,3,1,,170466056,3357,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
682,743239,2,1,,170466056,3357,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
683,743240,2,1,,170466056,3357,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
684,743241,2,1,,170466056,3357,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
685,743242,2,1,,170466056,3357,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
686,743244,1,1,,144206106,3357,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
687,743344,1,1,,50112812,3357,Inactive,,,0.0042,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
688,743345,1,1,,50112812,3357,Inactive,,,0.0053,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
689,743346,1,1,,50112812,3357,Inactive,,,11.8754,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
690,743347,1,1,,50112812,3357,Inactive,,,4.7277,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
691,748609,1,2,,103163873,3357,Active,,,,,Antibacterial activity against tolC-deficient Enterobacter aerogenes EA298 assessed as growth inhibition after 18 hrs by two-fold serial dilution method,Other,24900708.0,
692,748610,1,2,,103163873,3357,Unspecified,,,,,Antibacterial activity against multidrug-resistant Enterobacter aerogenes EA289 overexpressing AcrAB-tolC assessed as growth inhibition after 18 hrs by two-fold serial dilution method,Other,24900708.0,
693,748611,1,2,,103163873,3357,Active,,,,,Antibacterial activity against acrAB-deficient Escherichia coli AG100A assessed as growth inhibition after 18 hrs by two-fold serial dilution method,Other,24900708.0,
694,748612,1,2,,103163873,3357,Active,,,,,Antibacterial activity against wild type Escherichia coli AG100 assessed as growth inhibition after 18 hrs by two-fold serial dilution method,Other,24900708.0,
695,781329,1,2,,103163873,3357,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by other workers,Other,24249037.0,
696,781330,1,2,,103163873,3357,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by potentiometric titration,Other,24249037.0,
697,1079931,1,1,,103163873,3357,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
698,1079932,1,1,,103163873,3357,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
699,1079933,1,1,,103163873,3357,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
700,1079934,1,1,,103163873,3357,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
701,1079935,1,1,,103163873,3357,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
702,1079936,1,1,,103163873,3357,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
703,1079937,1,1,,103163873,3357,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
704,1079938,1,1,,103163873,3357,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
705,1079939,1,1,,103163873,3357,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
706,1079940,1,1,,103163873,3357,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
707,1079941,1,1,,103163873,3357,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
708,1079942,1,1,,103163873,3357,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
709,1079943,1,1,,103163873,3357,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
710,1079944,1,1,,103163873,3357,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
711,1079945,1,1,,103163873,3357,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
712,1079946,1,1,,103163873,3357,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
713,1079947,1,1,,103163873,3357,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
714,1079948,1,1,,103163873,3357,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
715,1079949,1,1,,103163873,3357,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
716,1117298,1,2,,170466056,3357,Inactive,,,0.7079,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
717,1117304,1,2,,170466056,3357,Inactive,,,8.9125,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
718,1117305,1,2,,170466056,3357,Inactive,,,2.8184,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
719,1117310,1,1,,170466056,3357,Inactive,,,0.707946,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
720,1117312,1,1,,170466056,3357,Inactive,,,2.81838,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
721,1117314,1,1,,170466056,3357,Inactive,,,8.912510000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
722,1117319,1,2,,26719809,3357,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
723,1117319,1,2,,26719809,3357,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
724,1117326,1,1,,170466056,3357,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
725,1117329,1,1,,170466056,3357,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
726,1117336,1,1,,170466056,3357,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
727,1117340,1,1,,170466056,3357,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
728,1117341,1,1,,170466056,3357,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
729,1117342,1,1,,170466056,3357,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
730,1117343,1,1,,170466056,3357,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
731,1117346,1,1,,170466056,3357,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
732,1159386,1,2,,103163873,3357,Unspecified,,,,,ASTRAZENECA: Most basic pKa value (pKa B1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Bases: >= 2.,Other,,
733,1159399,1,2,,103163873,3357,Unspecified,,,,,ASTRAZENECA: Most acidic pKa value (pKa A1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Acids: <= 11.,Other,,
734,1159509,1,1,,170466056,3357,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
735,1159515,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
736,1159516,1,1,,170466056,3357,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
737,1159517,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
738,1159518,1,1,,170466056,3357,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
739,1159519,1,1,,170466056,3357,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
740,1159520,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
741,1159521,1,1,,170466056,3357,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
742,1159523,1,1,,170466056,3357,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
743,1159525,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
744,1159526,1,1,,170466056,3357,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
745,1159527,1,1,,170466056,3357,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
746,1159528,1,1,,170466056,3357,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
747,1159529,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
748,1159531,1,1,,170466056,3357,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
749,1159551,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
750,1159552,1,1,,170466056,3357,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
751,1159553,2,1,,170466056,3357,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
752,1159555,1,1,,170466056,3357,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
753,1159614,1,2,,170466056,3357,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
754,1224824,1,1,,50112812,3357,Inactive,,,4.6859,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
755,1224825,1,1,,50112812,3357,Inactive,,,0.0042,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
756,1224834,3,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
757,1224835,1,1,,170466056,3357,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
758,1224836,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
759,1224837,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
760,1224838,1,1,,170466056,3357,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
761,1224839,1,1,,170466056,3357,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
762,1224840,3,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
763,1224841,3,1,,170466056,3357,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
764,1224842,3,1,,170466056,3357,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
765,1224843,1,1,,170466056,3357,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
766,1224844,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
767,1224845,1,1,,170466056,3357,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
768,1224846,1,1,,170466056,3357,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
769,1224847,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
770,1224848,3,1,,170466056,3357,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
771,1224849,3,1,,170466056,3357,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
772,1224857,2,1,,50112812,3357,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
773,1224857,2,1,,170466056,3357,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
774,1224859,2,1,,50112812,3357,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
775,1224859,2,1,,170466056,3357,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
776,1224863,1,1,,176484364,3357,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
777,1224863,1,1,,176484859,3357,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
778,1224867,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
779,1224868,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
780,1224869,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
781,1224870,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
782,1224871,1,1,,170466056,3357,Inconclusive,,,5.3538,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
783,1224872,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
784,1224873,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
785,1224874,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
786,1224875,1,1,,170466056,3357,Active,,,5.3538,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
787,1224876,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
788,1224877,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
789,1224878,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
790,1224879,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
791,1224880,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
792,1224881,1,1,,170466056,3357,Inconclusive,,,5.3538,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
793,1224882,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
794,1224883,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
795,1224884,1,1,,170466056,3357,Inconclusive,,,5.3538,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
796,1224885,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
797,1224886,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
798,1224887,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
799,1224888,1,1,,170466056,3357,Active,,,5.3538,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
800,1224889,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
801,1224890,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
802,1224892,1,1,,170466056,3357,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
803,1224893,1,1,,170466056,3357,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
804,1224894,1,1,,170466056,3357,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
805,1224895,1,1,,170466056,3357,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
806,1224896,1,1,,170466056,3357,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
807,1224905,2,1,,92309164,3357,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
808,1224905,2,1,,92309164,3357,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
809,1259241,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
810,1259242,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
811,1259243,1,1,,170466056,3357,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
812,1259244,1,1,,170466056,3357,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
813,1259247,1,1,,170466056,3357,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
814,1259248,1,1,,170466056,3357,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
815,1259252,1,1,,50112812,3357,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
816,1259253,1,1,,50112812,3357,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
817,1259255,1,1,,50112812,3357,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
818,1259256,1,1,,50112812,3357,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
819,1259310,1,1,,321946097,3357,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
820,1259310,1,1,,333472949,3357,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
821,1259344,1,1,,144206106,3357,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
822,1259355,1,1,,50112812,3357,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
823,1259356,1,1,,50112812,3357,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
824,1259364,1,1,,170466056,3357,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
825,1259365,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
826,1259366,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
827,1259367,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
828,1259368,1,1,,170466056,3357,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
829,1259369,1,1,,170466056,3357,Inactive,109731339.0,2737.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
830,1259377,1,1,,170466056,3357,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
831,1259378,1,1,,170466056,3357,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
832,1259379,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
833,1259380,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
834,1259381,1,1,,170466056,3357,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
835,1259382,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
836,1259383,1,1,,170466056,3357,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
837,1259384,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
838,1259385,1,1,,170466056,3357,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
839,1259386,1,1,,170466056,3357,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
840,1259387,1,1,,170466056,3357,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
841,1259388,1,1,,170466056,3357,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
842,1259390,1,1,,170466056,3357,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
843,1259391,1,1,,170466056,3357,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
844,1259392,1,1,,170466056,3357,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
845,1259393,1,1,,170466056,3357,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
846,1259394,1,1,,170466056,3357,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
847,1259395,1,1,,170466056,3357,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
848,1259396,1,1,,170466056,3357,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
849,1259400,1,1,,170466056,3357,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
850,1259401,1,1,,170466056,3357,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
851,1259402,1,1,,170466056,3357,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
852,1259403,1,1,,170466056,3357,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
853,1259404,1,1,,170466056,3357,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
854,1259407,1,1,,363901922,3357,Inactive,,,,,CCRIS mutagenicity studies,Other,,
855,1259409,1,1,,363901922,3357,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
856,1259416,1,2,,340079933,3357,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
857,1259421,1,1,,340079932,3357,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
858,1259421,1,1,,340079933,3357,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
859,1259423,1,2,,354875895,3357,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
